ALB and chronic kidney disease: The efficacy and safety of dapagliflozin in addition to standard therapy in patients with CKD and albuminuria [eGFR 25–75 mL/min/1.73 m2; urinary albumin-to-creatine ratio (UACR) ≥200 mg/g] was investigated in the Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial [13].